Resources Repository
-
OrganizationWeb Portal 2024International Network of Agencies for Health Technology Assessment
International Network of Agencies for Health Technology Assessment (INAHTA) is a network of 52 Health …
International Network of Agencies for Health Technology Assessment (INAHTA) is a network of 52 Health technology Assessment (HTA) agencies that support health system decision making. Among the goals of the network is to support best practices and to foster knowledge exchange and learning across HTA communities. INAHTA provides briefs, checklists, and impact reports which are publicly available.
Technology Assessment | Health Systems | Science/Technology -
Tutorial/PrimerInteractive, Teaching Resource 2017Health Technology Assessment (HTA) Glossary
The purpose of the HTA Glossary is to give the Health Technology Assessment (HTA) community …
The purpose of the HTA Glossary is to give the Health Technology Assessment (HTA) community – both producers and users of health technology assessment information – a common vocabulary. The HTA glossary is an official collaboration between International Network of Agencies for Health Technology Assessment (INAHTA), Health Technology Assessment international (HTAi) and other partner organizations. The English version of the HTA Glossary is coordinated by Adelaide Health Technology Assessment (AHTA), the French version by l'Institut…
Technology Assessment | Health/Medicine | High School | College | Graduate | Doctoral | Professional | Policy Translation -
ReviewPublication 2016Cost-Effectiveness Studies Reporting Cost-per-DALY Averted
This is a systematic review of cost-effectiveness studies reporting cost-per-DALY averted from 2000 through 2015 …
This is a systematic review of cost-effectiveness studies reporting cost-per-DALY averted from 2000 through 2015 conducted using the Global Health Cost-Effectiveness Analysis (GHCEA) Registry. Authors summarized descriptive characteristics on study methodology. They analyzed a) the types of costs included, b) study quality and c) the correlation between diseases researched and the burden of disease in different world regions. 479 cost-per-DALY averted studies were published from 2000 through 2015, with studies from Sub-Saharan Africa representing the largest portion…
Health Outcomes | Cost-Effectiveness Analysis | Health Systems | Health/Medicine | Global -
ArticlePublication 2016Health Gains & Financial Protection from Ethiopian Mental Health Strategy: An ECEA
Using the extended cost-effectiveness analysis (ECEA), this paper evaluates the impacts of fully publicly financed …
Using the extended cost-effectiveness analysis (ECEA), this paper evaluates the impacts of fully publicly financed care for depression, bipolar disorder, schizophrenia and epilepsy as part of the mental and neurological package (MN) of the National Mental Health Strategy in Ethiopia. The following outcomes were estimated disaggregated across wealth quintiles: (1) healthy-life-years (HALYs) gained; (2) household out-of-pocket (OOP) expenditures averted (3) expected financial risk protection (FRP); and (4) productivity impact. The MN package is expected to…
Health Outcomes | Costing Methods | Cost-Effectiveness Analysis | Mental Health | Economics/Finance | Health/Medicine | Sub-Saharan Africa -
GuidelinesPublication 2016Decision Models in Clinical Preventive Services Recommendations
The U.S. Preventive Services Task Force (USPSTF) develops evidence-based recommendations about preventive care based on …
The U.S. Preventive Services Task Force (USPSTF) develops evidence-based recommendations about preventive care based on comprehensive systematic reviews of the best available evidence. Decision models provide a complementary, quantitative approach to support the USPSTF as it deliberates about the evidence and develops recommendations for clinical and policy use. This article describes the rationale for using modeling, an approach to selecting topics for modeling, and how modeling may inform recommendations about clinical preventive services.
Health Outcomes | Evidence Synthesis | Mathematical Models | Decision Analysis | Health Systems | Policy/Regulation | Health/Medicine | North America -
GuidelinesPublication 2016Second Panel on Cost-Effectiveness in Health and Medicine
This article provides an overview of the main recommendations of the 2016 Second Panel on …
This article provides an overview of the main recommendations of the 2016 Second Panel on Cost-Effectiveness in Health and Medicine. In 1993, the U.S. Public Health Service convened the first panel of experts to review the state of cost-effectiveness analysis and to develop guidelines for its use in health, to improve quality and promote comparability. Scientists and scholars in economics, clinical medicine, ethics, and statistics met to share expertise and develop recommendations by consensus. The…
Technology Assessment | Priority Setting/Ethics | Costing Methods | Evidence Synthesis | Cost-Effectiveness Analysis | Health/Medicine | North America -
ArticlePublication 2016Quality Improvement for Cardiovascular Disease Care in Low- and Middle-Income Countries: A Systematic Review
The majority of global cardiovascular disease (CVD) burden falls on people living in low- and …
The majority of global cardiovascular disease (CVD) burden falls on people living in low- and middle-income countries (LMICs). As part of the Disease Control Priorities Three (DCP3) Study efforts addressing quality improvement, the authors reviewed and summarized currently available evidence on interventions to improve quality of clinic-based CVD prevention and management in LMICs. Using a narrative review of published comparative clinical trials that evaluated efficacy or effectiveness of clinic-based CVD prevention and management quality improvement…
Health Outcomes | Evidence Synthesis | Chronic Disease/Risk | Health Systems | Health/Medicine | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific -
Lesson/ModuleWeb Portal, Teaching Resource 2016Placing a Bet: New Therapy for Parkinson's Disease
This module is intended for use by business school students. It examines the decision-making process …
This module is intended for use by business school students. It examines the decision-making process at a pharmaceutical company as its chief operating officer decides whether to invest in the development and licensing of a promising treatment for Parkinson’s disease. The module is structured around a drug development case that provides students with opportunities to: (1) analyze a rich and realistic description of the complex scientific and medical results associated with a promising therapeutic molecule…
Technology Assessment | Test Performance | Chronic Disease/Risk | Policy/Regulation | Business/Industry | Government/Law | Health/Medicine | Science/Technology | Global | North America | College | Graduate | Doctoral | Critical Thinking/Analysis | Decision Making/Leadership | Quantitative Literacy -
Lesson/ModuleWeb Portal, Teaching Resource 2016Educational Module: Drug-Induced Birth Defects
Using the currently topical issue of whether SSRI (Selective Serotonin Reuptake Inhibitor) anti-depressants cause birth …
Using the currently topical issue of whether SSRI (Selective Serotonin Reuptake Inhibitor) anti-depressants cause birth defects, the module aims to provide students with a general understanding of the following: (1) human risk factor causation as determined by epidemiologic methods; (2) the limits of non-human toxicological evidence to the assessment of causality in humans; (3) the importance of pharmacovigilance for all medications; (4) special difficulties in identifying causes of human birth defects; (5) the importance of…
Health Outcomes | Evidence Synthesis | Risk Analysis | Child/Nutrition | Chronic Disease/Risk | Government/Law | Health/Medicine | Science/Technology | Global | North America | College | Graduate | Doctoral | Critical Thinking/Analysis | Quantitative Literacy